Objectives: To determine the frequency of incidentally diagnosed carcinoma prostate in prostatic
specimens removed by transurethral approach for benign prostatic
prostate cancer*[tiab] OR prostate carcinoma*[tiab] OR prostate neoplas*[tiab] OR prostate tumor*[tiab] OR prostate tumour*[tiab] OR prostate malignan*[tiab] OR prostate adeno*[tiab] OR prostatic
cancer*[tiab] OR prostatic
carcinoma*[tiab] OR prostatic
neoplas*[tiab] OR prostatic
tumor*[tiab] OR prostatic
tumour*[tiab] OR prostatic
malignan*[tiab] OR prostatic
1] In developing countries even though prostatic
carcinoma is less common, its incidence and mortality is on the rise.
hyperplasia (BPH) and prostatic
adenocarcinoma are very frequent prostatic
diseases in elderly men in their sixties and responsible for considerable morbidity and mortality.
Background and Objectives: Urinary Retention (UR) is one of the most serious complication of benign prostatic
hyperplasia (BPH), causing resistance in urine flow and hence results in painful urination.
The product is indicated as monotherapy for the treatment of symptomatic benign prostatic
hyperplasia in men with an enlarged prostate to improve symptoms, decrease the risk of acute urinary retention and reduce the risk of the need for benign prostatic
hyperplasia -related surgery.
These signs should not be ignored or overlooked as they can indicate serious problems, including benign prostatic
hyperplasia (BPH), prostatitis, and even prostate cancer.
8 cm was noted within the prostate located in the midline, which was communicating with the prostatic
urethra (Figures 1a, 1b).
diseases are common in old intact dogs.
Global Markets Direct's, 'Benign Prostatic
Hyperplasia - Pipeline Review, H2 2015', provides an overview of the Benign Prostatic
Hyperplasia's therapeutic pipeline.
On one end of this spectrum, intraductal carcinoma of the prostate (IDC-P) is often associated with late-stage, high-grade invasive prostatic
adenocarcinoma and requires either definitive therapy or immediate rebiopsy.
Background: The clinical failure after prostatic
artery embolization (PAE) with conventional particles was relatively high, in treatment for lower urinary tract symptoms (LUTS) due to benign prostatic